Akorn, Inc.
https://www.akorn.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Akorn, Inc.
Merus Gains Momentum Ahead Of Keytruda Combination Results
Results in head and neck cancer for its lead bispecific antibody are expected at ASCO, with signs the FDA could accept an accelerated approval application based only on overall response rate data.
Under LG Chem’s Wing, AVEO Oncology Steps On R&D Gas Pedal
With the integration with new parent LG Chem having gone "smoothly," AVEO Oncology is accelerating R&D efforts by beginning a pivotal Phase III trial with a combination of its novel candidate for head and neck cancer.
In Vivo’s Deals Of The Year: Cast Your Vote!
It is time for In Vivo's 16th annual Deals of the Year contest. We've selected 12 nominees across three categories – Top M&A, Top Alliance and Top Financing – and you get to pick the winners.
VC Fundraising Fell In Q4 But There Are Glimmers Of Hope For 2024
Evaluate’s fourth quarter data show that biopharma venture capital fundraising fell from $4.28bn in in Q3, but there was a rise in smaller deals and financial market conditions are poised for a turnaround.
Company Information
- Industry
- Distributors
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Hi-Tech Pharmacal
- Oak Pharmaceuticals, Inc., VersaPharm
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice